Investigators hope results from the FAST trial will lead to a rethink of boxed warnings on the drug.
Concern over elevated odds of severe disease might be unfounded, conference told.
An investigational monoclonal antibody that inhibits GM-CSF receptor alpha shows promise, researchers say.
A study shows improvements in patient pain and function with few serious adverse events, researchers say.
The analysis in people with AF suggests a NOAC might be the better option for those at risk of osteoarthritis, authors say.
Extension trial in patients with inadequate response to methotrexate finds no new safety signals, researchers report.
Up to a quarter of rheumatology patients were disadvantaged in some regions, a global survey suggests.
Patients can be reassured that the treatment will not precipitate the need for surgery, researchers say.
The study in patients with rheumatoid arthritis and lupus finds no association with prolonged QT interval.
The agent could be considered if usual treatment fails, researchers say after a randomised trial.